

## Table of Contents

Number	Title
1	Table 00: Comments
2	Table 01: Study population and enrolment information
3	Table 02: Patients by region, country, and cohort
4	Table 03 : Demographic Characteristics
5	Table 04 : Care setting , Type of AF and Insurance
6	Table 05 : Vital signs and life style
7	Table 06 : Clinical History
8	Table 07 : Treatment for stroke prophylaxis
9	Table 08: Treatment
10	Table 09 : Risk scores
11	Table 10: Treatment at baseline by CHA2DS2-VASc score
12	Table 11: Treatment at baseline by HAS-BLED score
13	Table 12: INR values and time in therapeutic range (TTR) during the first year of follow-up Cohorts 1 to 4
14	Table 13 :Event rates during the first year of follow-up Cohorts 1 to 4
15	Table 14: Cause of death during the first year of follow-up Cohorts 1 to 4
16	Table 15: Type of stroke during the first year of follow-up Cohorts 1 to 4
17	Table 16 : Mortality rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4
18	Table 17 : Stroke/SE rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4
19	Table 18 : Major bleeding rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4

### Table 00: Comments

- 1 The data was extracted from the GARFIELD-AF registry database on 28 JUL 2016
- 2 The data includes retrospective patients in cohort 1 and prospective patients in cohort 1, 2, 3, 4 and 5
- 3 The variable 'Congestive heart failure' was split into 'History of CHF' and 'Current CHF' in cohorts 3, 4 and 5. History of and/or current CHF were used to identify CHF in cohort 3, 4 and 5 patients (Table 6)
- 4 The variable 'Coronary artery disease' was split into 'History of CAD' and 'Current CAD' in cohorts 3, 4 and 5. History of and/or current CAD were used to identify CAD in cohort 3, 4 and 5 patients (Table 6)
- 5 The variable 'Other thromboembolism' is not recorded for patients in cohort 3, 4 and 5
- 6 The option 'None' was added in the CRF for the 'Chronic renal disease' field in cohort 3, 4 and 5. The percentages for the variable 'Moderate to severe CKD' are estimated assuming that patients with 'unknown' stage of CKD are without 'Moderate to severe CKD' (Table 6)
- 7 Table 7 describes the baseline treatment for stroke prophylaxis. For each treatment group identifier options are mutually exclusive. The option 'unknown' includes combination of treatments
- 8 Table 8 shows the baseline treatment for stroke prophylaxis with non mutually exclusive groups
- 9 Table 12 shows INR values and TTR for patients treated with VKA±AP at baseline. INR readings during the first year of follow-up were included in the analysis. Values less than 0.8 or greater than 20 were removed since these values may not be plausible. Patients on VKA±AP at enrolment but with fewer than three readings during the follow-up were excluded from the analysis. Patient-level TTR was estimated by linear interpolation according to Rosendaal et al (1993), using 2.0-3.0 as the target INR range. TTR was estimated using INR readings until discontinuation or interruption of VKA or the end of follow-up. In addition, TTR was estimated between two consecutive INR readings only if the interval did not exceed 90 days.
- 10 Tables 13 and 14 describe events during the first year of follow-up for patients in cohorts 1-4. Only the first occurrence of each event was taken into account.
- 11 Table 13 Congestive heart failure during the follow-up includes new congestive heart failure or worsening of pre-existing congestive heart failure.

**Table 01: Study population and enrolment information  
Full Analysis Dataset : BRAZIL**

Number of prospective patients (C1+C2+C3+C4+C5 )	1040
Number of enrolling sites	41
Number of enrolling countries	1
Enrolment period	18FEB2011 - 26JUL2016
Duration of enrolment (months)	65.2

**Table 02: Patients by region, country, and cohort  
Full Analysis Dataset : BRAZIL**

Region	Country	Cohort 1 Retrospective patients (N=146)	Cohort 1 Prospective patients (N=97)	Cohort 2 (N=248)	Cohort 3 (N=230)	Cohort 4 (N=231)	Cohort 5 (N=234)	Total Prospective patients Cohorts 1 to 5 (N=1040)	Total Prospective patients Cohorts 1 to 4 (N=806)
Latin America	Brazil	146	97	248	230	231	234	1040	806

**Table 03 : Demographic Characteristics  
Full Analysis Dataset : BRAZIL**

Variable	Statistics	Cohort 1 Retrospective patients (N=146) (n %)	Cohort 1 Prospective patients (N=97) (n %)	Cohort 2 (N=248) (n %)	Cohort 3 (N=230) (n %)	Cohort 4 (N=231) (n %)	Cohort 5 (N=234) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1040)	Total Prospective patients Cohorts 1 to 4 (N=806)
Sex, n(%)	n (missing)	146 (0)	97 (0)	248 (0)	230 (0)	231 (0)	234 (0)	1040 (0)	806 (0)
	Male	81 (55.5)	50 (51.5)	136 (54.8)	134 (58.3)	123 (53.2)	125 (53.4)	568 (54.6)	443 (55.0)
	Female	65 (44.5)	47 (48.5)	112 (45.2)	96 (41.7)	108 (46.8)	109 (46.6)	472 (45.4)	363 (45.0)
Age at Diagnosis (Years)	n (missing)	146 (0)	97 (0)	248 (0)	230 (0)	231 (0)	234 (0)	1040 (0)	806 (0)
	Mean (SD)	68.1 (11.6)	69.4 (11.0)	66.9 (13.4)	67.4 (13.0)	68.4 (12.2)	68.0 (13.0)	67.8 (12.8)	67.8 (12.7)
	Median (IQR)	69.0 (62.0 to 77.0)	70.0 (61.0 to 78.0)	68.0 (58.0 to 77.0)	69.0 (60.0 to 77.0)	69.0 (61.0 to 77.0)	68.0 (60.0 to 77.0)	69.0 (60.0 to 77.0)	69.0 (60.0 to 77.0)
	Min to Max	28 to 99	36 to 95	27 to 98	26 to 93	26 to 99	28 to 96	26 to 99	26 to 99
Age Group, n(%)	n (missing)	146 (0)	97 (0)	248 (0)	230 (0)	231 (0)	234 (0)	1040 (0)	806 (0)
	<65	48 (32.9)	32 (33.0)	97 (39.1)	84 (36.5)	86 (37.2)	81 (34.6)	380 (36.5)	299 (37.1)
	65-74	56 (38.4)	32 (33.0)	72 (29.0)	72 (31.3)	66 (28.6)	72 (30.8)	314 (30.2)	242 (30.0)
	>=75	42 (28.8)	33 (34.0)	79 (31.9)	74 (32.2)	79 (34.2)	81 (34.6)	346 (33.3)	265 (32.9)
Time since AF Diagnosis (Weeks)	n (missing)	146 (0)	77 (20)	215 (33)	184 (46)	192 (39)	212 (22)	880 (160)	668 (138)
	Mean (SD)	60.93 (22.33)	2.04 (1.93)	2.08 (1.66)	1.73 (1.56)	1.89 (1.73)	2.12 (1.66)	1.97 (1.68)	1.92 (1.69)
	Median (IQR)	56.10 (41.70 to 78.20)	1.20 (0.40 to 4.10)	1.50 (0.70 to 3.40)	1.20 (0.50 to 2.50)	1.20 (0.40 to 3.10)	1.70 (0.80 to 3.20)	1.40 (0.50 to 3.10)	1.20 (0.50 to 3.10)
	Min to Max	26.1 to 104.2	0.1 to 6.0	0.1 to 6.0	0.1 to 6.0	0.1 to 6.0	0.1 to 6.0	0.1 to 6.0	0.1 to 6.0
Race, n(%)	n (missing)	141 (0)	96 (0)	221 (0)	206 (0)	202 (0)	214 (0)	939 (0)	725 (0)
	Caucasian	47 (33.3)	51 (53.1)	81 (36.7)	135 (65.5)	125 (61.9)	108 (50.5)	500 (53.2)	392 (54.1)
	Hispanic/Latino	68 (48.2)	41 (42.7)	93 (42.1)	44 (21.4)	51 (25.2)	79 (36.9)	308 (32.8)	229 (31.6)
	Afro-Caribbean	10 (7.1)	1 (1.0)	8 (3.6)	6 (2.9)	4 (2.0)	14 (6.5)	33 (3.5)	19 (2.6)

**Table 03 : Demographic Characteristics  
Full Analysis Dataset : BRAZIL**

Variable	Statistics	Cohort 1 Retrospective patients (N=146) (n %)	Cohort 1 Prospective patients (N=97) (n %)	Cohort 2 (N=248) (n %)	Cohort 3 (N=230) (n %)	Cohort 4 (N=231) (n %)	Cohort 5 (N=234) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1040)	Total Prospective patients Cohorts 1 to 4 (N=806)
	Asian (Not Chinese)	2 (1.4)	1 (1.0)	3 (1.4)	2 (1.0)	1 (0.5)	1 (0.5)	8 (0.9)	7 (1.0)
	Chinese	-	-	-	1 (0.5)	-	-	1 (0.1)	1 (0.1)
	Mixed/Other	14 (9.9)	2 (2.1)	36 (16.3)	18 (8.7)	21 (10.4)	12 (5.6)	89 (9.5)	77 (10.6)
	Unknown	5	1	27	24	29	20	101	81
Region, n(%)	n (missing)	146 (0)	97 (0)	248 (0)	230 (0)	231 (0)	234 (0)	1040 (0)	806 (0)
	Latin America	146 (100.0)	97 (100.0)	248 (100.0)	230 (100.0)	231 (100.0)	234 (100.0)	1040 (100.0)	806 (100.0)

**Table 04 : Care setting , Type of AF and Insurance  
Full Analysis Dataset : BRAZIL**

Variable	Statistics	Cohort 1 Retrospective patients (N=146) (n %)	Cohort 1 Prospective patients (N=97) (n %)	Cohort 2 (N=248) (n %)	Cohort 3 (N=230) (n %)	Cohort 4 (N=231) (n %)	Cohort 5 (N=234) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1040)	Total Prospective patients Cohorts 1 to 4 (N=806)
Care Setting Speciality at Diagnosis, n(%)	n (missing)	146 (0)	97 (0)	248 (0)	230 (0)	231 (0)	234 (0)	1040 (0)	806 (0)
	Internal Medicine	7 (4.8)	6 (6.2)	21 (8.5)	14 (6.1)	33 (14.3)	23 (9.8)	97 (9.3)	74 (9.2)
	Cardiology	128 (87.7)	80 (82.5)	195 (78.6)	195 (84.8)	189 (81.8)	199 (85.0)	858 (82.5)	659 (81.8)
	Neurology	3 (2.1)	1 (1.0)	2 (0.8)	5 (2.2)	2 (0.9)	2 (0.9)	12 (1.2)	10 (1.2)
	Geriatrics	-	-	1 (0.4)	1 (0.4)	-	-	2 (0.2)	2 (0.2)
	Primary Care/General Practice	8 (5.5)	10 (10.3)	29 (11.7)	15 (6.5)	7 (3.0)	10 (4.3)	71 (6.8)	61 (7.6)
Care Setting Location at Diagnosis, n(%)	n (missing)	141 (0)	97 (0)	248 (0)	230 (0)	231 (0)	234 (0)	1040 (0)	806 (0)
	Hospital	38 (27.0)	37 (38.1)	98 (39.5)	104 (45.2)	110 (47.6)	114 (48.7)	463 (44.5)	349 (43.3)
	Office	77 (54.6)	31 (32.0)	68 (27.4)	65 (28.3)	47 (20.3)	65 (27.8)	276 (26.5)	211 (26.2)
	Anticoagulation clinic/thrombosi s centre	7 (5.0)	2 (2.1)	2 (0.8)	-	-	-	4 (0.4)	4 (0.5)
	Emergency room	19 (13.5)	27 (27.8)	80 (32.3)	61 (26.5)	74 (32.0)	55 (23.5)	297 (28.6)	242 (30.0)
	Unknown	5	-	-	-	-	-	-	-
Type of AF Diagnosed, n(%)	n (missing)	146 (0)	97 (0)	248 (0)	230 (0)	231 (0)	234 (0)	1040 (0)	806 (0)
	Permanent	63 (43.2)	20 (20.6)	14 (5.6)	14 (6.1)	14 (6.1)	23 (9.8)	85 (8.2)	62 (7.7)
	Persistent	35 (24.0)	12 (12.4)	39 (15.7)	28 (12.2)	32 (13.9)	35 (15.0)	146 (14.0)	111 (13.8)
	Paroxysmal	42 (28.8)	23 (23.7)	69 (27.8)	67 (29.1)	53 (22.9)	50 (21.4)	262 (25.2)	212 (26.3)
	New	6 (4.1)	42 (43.3)	126 (50.8)	121 (52.6)	132 (57.1)	126 (53.8)	547 (52.6)	421 (52.2)

**Table 04 : Care setting , Type of AF and Insurance  
Full Analysis Dataset : BRAZIL**

Variable	Statistics	Cohort 1 Retrospective patients (N=146) (n %)	Cohort 1 Prospective patients (N=97) (n %)	Cohort 2 (N=248) (n %)	Cohort 3 (N=230) (n %)	Cohort 4 (N=231) (n %)	Cohort 5 (N=234) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1040)	Total Prospective patients Cohorts 1 to 4 (N=806)
Treatment Costs, n(%)	n (missing)	-	-	163 (0)	229 (0)	222 (0)	226 (0)	840 (0)	614 (0)
	Public insurance	-	-	77 (47.2)	125 (54.6)	109 (49.1)	106 (46.9)	417 (49.6)	311 (50.7)
	Private (insurance)	-	-	74 (45.4)	85 (37.1)	91 (41.0)	102 (45.1)	352 (41.9)	250 (40.7)
	Private (out of pocke	-	-	9 (5.5)	7 (3.1)	10 (4.5)	14 (6.2)	40 (4.8)	26 (4.2)
	Combination	-	-	3 (1.8)	12 (5.2)	12 (5.4)	4 (1.8)	31 (3.7)	27 (4.4)
	Unknown	146	97	85	1	9	8	200	192
Treatment Sector, n(%)	n (missing)	3 (0)	-	170 (0)	229 (0)	228 (0)	234 (0)	861 (0)	627 (0)
	In the public sector	-	-	84 (49.4)	132 (57.6)	126 (55.3)	119 (50.9)	461 (53.5)	342 (54.5)
	In the private sector	3 (100.0)	-	86 (50.6)	97 (42.4)	102 (44.7)	115 (49.1)	400 (46.5)	285 (45.5)
	Unknown	143	97	78	1	3	-	179	179



**Table 05 : Vital signs and life style**  
**Full Analysis Dataset : BRAZIL**

Variable	Statistics	Cohort 1 Retrospective patients (N=146) (n %)	Cohort 1 Prospective patients (N=97) (n %)	Cohort 2 (N=248) (n %)	Cohort 3 (N=230) (n %)	Cohort 4 (N=231) (n %)	Cohort 5 (N=234) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1040)	Total Prospective patients Cohorts 1 to 4 (N=806)
Height (cm)	n (missing)	111 (35)	86 (11)	168 (80)	145 (85)	173 (58)	174 (60)	746 (294)	572 (234)
	Mean (SD)	164.9 (8.6)	165.1 (10.1)	166.4 (9.3)	166.5 (10.0)	166.1 (10.2)	165.3 (10.3)	166.0 (10.0)	166.1 (9.9)
	Median (IQR)	165.0 (160.0 to 170.0)	165.0 (156.0 to 173.0)	165.0 (160.0 to 173.5)	166.0 (160.0 to 173.0)	165.0 (160.0 to 174.0)	165.0 (159.0 to 172.0)	165.0 (160.0 to 173.0)	165.0 (160.0 to 173.5)
	Min to Max	148 to 201	146 to 185	146 to 190	139 to 186	145 to 194	140 to 193	139 to 194	139 to 194
Weight (kg)	n (missing)	111 (35)	86 (11)	168 (80)	145 (85)	173 (58)	174 (60)	746 (294)	572 (234)
	Mean (SD)	76.3 (15.1)	73.8 (18.0)	78.2 (16.4)	79.6 (17.6)	77.1 (18.0)	78.1 (22.1)	77.7 (18.7)	77.5 (17.5)
	Median (IQR)	75.0 (65.0 to 85.0)	72.0 (62.0 to 81.0)	78.0 (66.5 to 87.0)	78.0 (69.0 to 89.0)	75.0 (66.0 to 88.0)	75.0 (64.0 to 85.0)	76.0 (65.0 to 86.0)	76.0 (66.0 to 87.0)
	Min to Max	47 to 144	41 to 125	37 to 150	45 to 156	36 to 155	42 to 210	36 to 210	36 to 156
BMI (kg/m <sup>2</sup> )	n (missing)	111 (35)	86 (11)	168 (80)	145 (85)	173 (58)	174 (60)	746 (294)	572 (234)
	Mean (SD)	28.0 (4.7)	27.1 (5.9)	28.2 (5.2)	28.7 (5.5)	27.9 (5.3)	28.5 (6.9)	28.2 (5.8)	28.1 (5.4)
	Median (IQR)	28.0 (25.0 to 31.0)	26.0 (23.0 to 30.0)	27.0 (25.0 to 31.0)	28.0 (25.0 to 31.0)	28.0 (25.0 to 31.0)	28.0 (24.0 to 31.0)	28.0 (24.0 to 31.0)	27.5 (24.0 to 31.0)
	Min to Max	19 to 39	18 to 50	17 to 46	17 to 47	17 to 44	17 to 73	17 to 73	17 to 50
BMI Category, n(%)	n (missing)	111 (35)	86 (11)	168 (80)	145 (85)	173 (58)	174 (60)	746 (294)	572 (234)
	<19	-	4 (4.7)	2 (1.2)	1 (0.7)	6 (3.5)	3 (1.7)	16 (2.1)	13 (2.3)
	19-<25	32 (28.8)	33 (38.4)	47 (28.0)	38 (26.2)	45 (26.0)	54 (31.0)	217 (29.1)	163 (28.5)
	25-<30	45 (40.5)	29 (33.7)	68 (40.5)	55 (37.9)	72 (41.6)	67 (38.5)	291 (39.0)	224 (39.2)
	30-<40	34 (30.6)	18 (20.9)	48 (28.6)	45 (31.0)	47 (27.2)	40 (23.0)	198 (26.5)	158 (27.6)
	>=40	-	2 (2.3)	3 (1.8)	6 (4.1)	3 (1.7)	10 (5.7)	24 (3.2)	14 (2.4)
Pulse (bpm)	n (missing)	124 (22)	93 (4)	214 (34)	206 (24)	212 (19)	207 (27)	932 (108)	725 (81)
	Mean (SD)	84.7 (22.0)	85.9 (24.5)	92.2 (30.0)	91.5 (26.9)	88.1 (28.4)	89.6 (27.5)	89.9 (27.9)	90.0 (28.0)
	Median (IQR)	80.0 (71.0 to 90.0)	80.0 (70.0 to 96.0)	83.0 (70.0 to 110.0)	82.5 (72.0 to 110.0)	80.0 (68.0 to 102.0)	80.0 (72.0 to 100.0)	80.0 (70.0 to 104.0)	80.0 (70.0 to 106.0)
	Min to Max	56 to 185	40 to 162	36 to 186	45 to 185	44 to 189	47 to 196	36 to 196	36 to 189

**Table 05 : Vital signs and life style**  
**Full Analysis Dataset : BRAZIL**

Variable	Statistics	Cohort 1 Retrospective patients (N=146) (n %)	Cohort 1 Prospective patients (N=97) (n %)	Cohort 2 (N=248) (n %)	Cohort 3 (N=230) (n %)	Cohort 4 (N=231) (n %)	Cohort 5 (N=234) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1040)	Total Prospective patients Cohorts 1 to 4 (N=806)
Systolic BP (mm Hg)	n (missing)	132 (14)	88 (9)	218 (30)	212 (18)	215 (16)	207 (27)	940 (100)	733 (73)
	Mean (SD)	132.1 (18.2)	130.0 (23.0)	131.0 (20.6)	130.6 (22.8)	129.6 (20.3)	128.9 (22.6)	130.0 (21.7)	130.4 (21.4)
	Median (IQR)	130.0 (120.0 to 140.0)	128.5 (114.5 to 145.0)	130.0 (120.0 to 140.0)	130.0 (120.0 to 140.0)	130.0 (120.0 to 140.0)	130.0 (120.0 to 140.0)	130.0 (120.0 to 140.0)	130.0 (120.0 to 140.0)
	Min to Max	90 to 200	84 to 210	80 to 220	70 to 240	76 to 181	80 to 220	70 to 240	70 to 240
Diastolic BP (mm Hg)	n (missing)	132 (14)	88 (9)	218 (30)	212 (18)	215 (16)	207 (27)	940 (100)	733 (73)
	Mean (SD)	82.6 (12.7)	79.7 (12.8)	79.8 (12.3)	79.5 (12.9)	77.8 (11.8)	78.1 (14.9)	78.9 (13.0)	79.1 (12.4)
	Median (IQR)	80.0 (75.5 to 90.0)	80.0 (70.0 to 89.0)	80.0 (70.0 to 88.0)	80.0 (70.0 to 86.5)	80.0 (70.0 to 81.0)	80.0 (70.0 to 86.0)	80.0 (70.0 to 85.0)	80.0 (70.0 to 85.0)
	Min to Max	60 to 140	57 to 110	39 to 120	40 to 140	40 to 121	42 to 130	39 to 140	39 to 140
LVEF (%)	n (missing)	106 (40)	61 (36)	161 (87)	145 (85)	140 (91)	152 (82)	659 (381)	507 (299)
	Mean (SD)	58.9 (12.9)	56.0 (14.2)	60.3 (12.4)	58.5 (14.0)	56.6 (15.1)	58.7 (13.6)	58.4 (13.8)	58.3 (13.9)
	Median (IQR)	61.5 (50.0 to 68.0)	59.0 (48.0 to 65.0)	64.0 (55.0 to 68.0)	60.0 (48.0 to 69.0)	62.0 (43.5 to 67.0)	61.0 (49.5 to 69.0)	62.0 (48.0 to 68.0)	62.0 (48.0 to 68.0)
	Min to Max	21 to 86	23 to 86	25 to 82	20 to 86	22 to 83	18 to 87	18 to 87	20 to 86
LVEF Category, n (missing) n(%)	n (missing)	106 (40)	61 (36)	161 (87)	145 (85)	140 (91)	152 (82)	659 (381)	507 (299)
	<40%	8 (7.5)	8 (13.1)	13 (8.1)	13 (9.0)	27 (19.3)	17 (11.2)	78 (11.8)	61 (12.0)
	>=40%	98 (92.5)	53 (86.9)	148 (91.9)	132 (91.0)	113 (80.7)	135 (88.8)	581 (88.2)	446 (88.0)
History of Hypertension, n(%)	n (missing)	146 (0)	97 (0)	248 (0)	226 (0)	231 (0)	234 (0)	1036 (0)	802 (0)
	No	29 (19.9)	17 (17.5)	53 (21.4)	39 (17.3)	39 (16.9)	50 (21.4)	198 (19.1)	148 (18.5)
	Yes	117 (80.1)	80 (82.5)	195 (78.6)	187 (82.7)	192 (83.1)	184 (78.6)	838 (80.9)	654 (81.5)

**Table 05 : Vital signs and life style**  
**Full Analysis Dataset : BRAZIL**

Variable	Statistics	Cohort 1 Retrospective patients (N=146) (n %)	Cohort 1 Prospective patients (N=97) (n %)	Cohort 2 (N=248) (n %)	Cohort 3 (N=230) (n %)	Cohort 4 (N=231) (n %)	Cohort 5 (N=234) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1040)	Total Prospective patients Cohorts 1 to 4 (N=806)
	Unknown	-	-	-	4	-	-	4	4
Alcohol Consumption, n(%)	n (missing)	138 (0)	94 (0)	224 (0)	206 (0)	211 (0)	212 (0)	947 (0)	735 (0)
	Abstinent	111 (80.4)	70 (74.5)	161 (71.9)	159 (77.2)	165 (78.2)	169 (79.7)	724 (76.5)	555 (75.5)
	Light	19 (13.8)	16 (17.0)	42 (18.8)	32 (15.5)	26 (12.3)	25 (11.8)	141 (14.9)	116 (15.8)
	Moderate	6 (4.3)	5 (5.3)	17 (7.6)	11 (5.3)	18 (8.5)	12 (5.7)	63 (6.7)	51 (6.9)
	Heavy	2 (1.4)	3 (3.2)	4 (1.8)	4 (1.9)	2 (0.9)	6 (2.8)	19 (2.0)	13 (1.8)
	Unknown	8	3	24	24	20	22	93	71
Smoker, n(%)	n (missing)	140 (0)	94 (0)	233 (0)	213 (0)	220 (0)	222 (0)	982 (0)	760 (0)
	No	88 (62.9)	62 (66.0)	154 (66.1)	140 (65.7)	153 (69.5)	161 (72.5)	670 (68.2)	509 (67.0)
	Ex-smoker	43 (30.7)	29 (30.9)	61 (26.2)	64 (30.0)	50 (22.7)	47 (21.2)	251 (25.6)	204 (26.8)
	Current smoker	9 (6.4)	3 (3.2)	18 (7.7)	9 (4.2)	17 (7.7)	14 (6.3)	61 (6.2)	47 (6.2)
	Unknown	6	3	15	17	11	12	58	46

**Table 06 : Clinical History**  
**Full Analysis Dataset : BRAZIL**

Variable	Statistics	Cohort 1 Retrospective patients (N=146) (n %)	Cohort 1 Prospective patients (N=97) (n %)	Cohort 2 (N=248) (n %)	Cohort 3 (N=230) (n %)	Cohort 4 (N=231) (n %)	Cohort 5 (N=234) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1040)	Total Prospective patients Cohorts 1 to 4 (N=806)
Congestive heart failure, n(%)	n (missing)	146 (0)	97 (0)	248 (0)	230 (0)	231 (0)	234 (0)	1040 (0)	806 (0)
	No	97 (66.4)	60 (61.9)	189 (76.2)	167 (72.6)	175 (75.8)	180 (76.9)	771 (74.1)	591 (73.3)
	Yes	49 (33.6)	37 (38.1)	59 (23.8)	63 (27.4)	56 (24.2)	54 (23.1)	269 (25.9)	215 (26.7)
Congestive Heart Failure NYHA Class, n(%)	n (missing)	46 (97)	37 (60)	50 (189)	56 (167)	47 (175)	44 (180)	234 (771)	190 (591)
	I	10 (21.7)	10 (27.0)	8 (16.0)	13 (23.2)	2 (4.3)	7 (15.9)	40 (17.1)	33 (17.4)
	II	26 (56.5)	14 (37.8)	29 (58.0)	29 (51.8)	29 (61.7)	18 (40.9)	119 (50.9)	101 (53.2)
	III	9 (19.6)	8 (21.6)	9 (18.0)	13 (23.2)	8 (17.0)	17 (38.6)	55 (23.5)	38 (20.0)
	IV	1 (2.2)	5 (13.5)	4 (8.0)	1 (1.8)	8 (17.0)	2 (4.5)	20 (8.5)	18 (9.5)
	Unknown	3	-	9	7	9	10	35	25
Coronary artery disease, n(%)	n (missing)	146 (0)	97 (0)	248 (0)	230 (0)	231 (0)	234 (0)	1040 (0)	806 (0)
	No	124 (84.9)	74 (76.3)	213 (85.9)	188 (81.7)	186 (80.5)	178 (76.1)	839 (80.7)	661 (82.0)
	Yes	22 (15.1)	23 (23.7)	35 (14.1)	42 (18.3)	45 (19.5)	56 (23.9)	201 (19.3)	145 (18.0)
Acute coronary syndrome, n(%)	n (missing)	146 (0)	97 (0)	248 (0)	223 (0)	226 (0)	231 (0)	1025 (0)	794 (0)
	No	134 (91.8)	85 (87.6)	234 (94.4)	201 (90.1)	200 (88.5)	196 (84.8)	916 (89.4)	720 (90.7)
	Yes	12 (8.2)	12 (12.4)	14 (5.6)	22 (9.9)	26 (11.5)	35 (15.2)	109 (10.6)	74 (9.3)
	Unknown	-	-	-	7	5	3	15	12
Carotid Occlusive Disease, n(%)	n (missing)	146 (0)	97 (0)	246 (0)	221 (0)	221 (0)	224 (0)	1009 (0)	785 (0)
	No	143 (97.9)	90 (92.8)	236 (95.9)	214 (96.8)	210 (95.0)	217 (96.9)	967 (95.8)	750 (95.5)

**Table 06 : Clinical History**  
**Full Analysis Dataset : BRAZIL**

Variable	Statistics	Cohort 1 Retrospective patients (N=146) (n %)	Cohort 1 Prospective patients (N=97) (n %)	Cohort 2 (N=248) (n %)	Cohort 3 (N=230) (n %)	Cohort 4 (N=231) (n %)	Cohort 5 (N=234) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1040)	Total Prospective patients Cohorts 1 to 4 (N=806)
	Yes	3 (2.1)	7 (7.2)	10 (4.1)	7 (3.2)	11 (5.0)	7 (3.1)	42 (4.2)	35 (4.5)
	Unknown	-	-	2	9	10	10	31	21
PE or DVT, n(%)	n (missing)	146 (0)	97 (0)	246 (0)	223 (0)	219 (0)	227 (0)	1012 (0)	785 (0)
	No	141 (96.6)	93 (95.9)	242 (98.4)	216 (96.9)	212 (96.8)	218 (96.0)	981 (96.9)	763 (97.2)
	Yes	5 (3.4)	4 (4.1)	4 (1.6)	7 (3.1)	7 (3.2)	9 (4.0)	31 (3.1)	22 (2.8)
	Unknown	-	-	2	7	12	7	28	21
Other Thromboemboli sm, n(%)	n (missing)	146 (0)	97 (0)	245 (3)	0 (230)	0 (231)	0 (234)	342 (698)	342 (464)
	No	146 (100.0)	95 (97.9)	245 (100.0)	-	-	-	340 (99.4)	340 (99.4)
	Yes	-	2 (2.1)	-	-	-	-	2 (0.6)	2 (0.6)
Systemic Embolization, n(%)	n (missing)	146 (0)	97 (0)	246 (0)	223 (0)	220 (0)	227 (0)	1013 (0)	786 (0)
	No	146 (100.0)	95 (97.9)	242 (98.4)	219 (98.2)	218 (99.1)	226 (99.6)	1000 (98.7)	774 (98.5)
	Yes	-	2 (2.1)	4 (1.6)	4 (1.8)	2 (0.9)	1 (0.4)	13 (1.3)	12 (1.5)
	Unknown	-	-	2	7	11	7	27	20
Coronary Artery Bypass Graft, n(%)	n (missing)	141 (0)	91 (0)	247 (0)	224 (0)	223 (0)	229 (0)	1014 (0)	785 (0)
	No	133 (94.3)	89 (97.8)	233 (94.3)	213 (95.1)	211 (94.6)	217 (94.8)	963 (95.0)	746 (95.0)
	Yes	8 (5.7)	2 (2.2)	14 (5.7)	11 (4.9)	12 (5.4)	12 (5.2)	51 (5.0)	39 (5.0)
	Unknown	5	6	1	6	8	5	26	21
Stroke/TIA, n(%)	n (missing)	146 (0)	97 (0)	248 (0)	230 (0)	231 (0)	234 (0)	1040 (0)	806 (0)

**Table 06 : Clinical History**  
**Full Analysis Dataset : BRAZIL**

Variable	Statistics	Cohort 1 Retrospective patients (N=146) (n %)	Cohort 1 Prospective patients (N=97) (n %)	Cohort 2 (N=248) (n %)	Cohort 3 (N=230) (n %)	Cohort 4 (N=231) (n %)	Cohort 5 (N=234) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1040)	Total Prospective patients Cohorts 1 to 4 (N=806)
	No	123 (84.2)	84 (86.6)	219 (88.3)	204 (88.7)	203 (87.9)	210 (89.7)	920 (88.5)	710 (88.1)
	Yes	23 (15.8)	13 (13.4)	29 (11.7)	26 (11.3)	28 (12.1)	24 (10.3)	120 (11.5)	96 (11.9)
Stroke, n(%)	n (missing)	146 (0)	97 (0)	247 (0)	229 (0)	228 (0)	229 (0)	1030 (0)	801 (0)
	No	128 (87.7)	90 (92.8)	229 (92.7)	211 (92.1)	212 (93.0)	213 (93.0)	955 (92.7)	742 (92.6)
	Yes	18 (12.3)	7 (7.2)	18 (7.3)	18 (7.9)	16 (7.0)	16 (7.0)	75 (7.3)	59 (7.4)
	Unknown	-	-	1	1	3	5	10	5
History of Bleeding, n(%)	n (missing)	146 (0)	97 (0)	247 (0)	229 (0)	228 (0)	233 (0)	1034 (0)	801 (0)
	No	136 (93.2)	86 (88.7)	238 (96.4)	220 (96.1)	220 (96.5)	224 (96.1)	988 (95.6)	764 (95.4)
	Yes	10 (6.8)	11 (11.3)	9 (3.6)	9 (3.9)	8 (3.5)	9 (3.9)	46 (4.4)	37 (4.6)
	Unknown	-	-	1	1	3	1	6	5
Hypercholester olaemia, n(%)	n (missing)	146 (0)	97 (0)	248 (0)	204 (0)	204 (0)	223 (0)	976 (0)	753 (0)
	No	76 (52.1)	52 (53.6)	151 (60.9)	125 (61.3)	112 (54.9)	128 (57.4)	568 (58.2)	440 (58.4)
	Yes	70 (47.9)	45 (46.4)	97 (39.1)	79 (38.7)	92 (45.1)	95 (42.6)	408 (41.8)	313 (41.6)
	Unknown	-	-	-	26	27	11	64	53
Diabetes, n(%)	n (missing)	146 (0)	97 (0)	248 (0)	230 (0)	231 (0)	234 (0)	1040 (0)	806 (0)
	No	109 (74.7)	78 (80.4)	194 (78.2)	171 (74.3)	162 (70.1)	174 (74.4)	779 (74.9)	605 (75.1)
	Type I	2 (1.4)	-	6 (2.4)	4 (1.7)	10 (4.3)	6 (2.6)	26 (2.5)	20 (2.5)
	Type II	35 (24.0)	19 (19.6)	48 (19.4)	55 (23.9)	59 (25.5)	54 (23.1)	235 (22.6)	181 (22.5)
Diabetes, n(%)	n (missing)	146 (0)	97 (0)	248 (0)	230 (0)	231 (0)	234 (0)	1040 (0)	806 (0)
	No	109 (74.7)	78 (80.4)	194 (78.2)	171 (74.3)	162 (70.1)	174 (74.4)	779 (74.9)	605 (75.1)
	Yes	37 (25.3)	19 (19.6)	54 (21.8)	59 (25.7)	69 (29.9)	60 (25.6)	261 (25.1)	201 (24.9)
Cirrhosis, n(%)	n (missing)	146 (0)	97 (0)	247 (0)	206 (0)	208 (0)	222 (0)	980 (0)	758 (0)
	No	146 (100.0)	97 (100.0)	247 (100.0)	205 (99.5)	207 (99.5)	221 (99.5)	977 (99.7)	756 (99.7)

**Table 06 : Clinical History**  
**Full Analysis Dataset : BRAZIL**

Variable	Statistics	Cohort 1 Retrospective patients (N=146) (n %)	Cohort 1 Prospective patients (N=97) (n %)	Cohort 2 (N=248) (n %)	Cohort 3 (N=230) (n %)	Cohort 4 (N=231) (n %)	Cohort 5 (N=234) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1040)	Total Prospective patients Cohorts 1 to 4 (N=806)
	Yes	-	-	-	1 (0.5)	1 (0.5)	1 (0.5)	3 (0.3)	2 (0.3)
	Unknown	-	-	1	24	23	12	60	48
Dementia, n(%)	n (missing)	146 (0)	97 (0)	246 (0)	219 (0)	225 (0)	227 (0)	1014 (0)	787 (0)
	No	146 (100.0)	95 (97.9)	244 (99.2)	218 (99.5)	223 (99.1)	221 (97.4)	1001 (98.7)	780 (99.1)
	Yes	-	2 (2.1)	2 (0.8)	1 (0.5)	2 (0.9)	6 (2.6)	13 (1.3)	7 (0.9)
	Unknown	-	-	2	11	6	7	26	19
Hyperthyroidis m, n(%)	n (missing)	146 (0)	97 (0)	248 (0)	202 (0)	198 (0)	213 (0)	958 (0)	745 (0)
	No	144 (98.6)	97 (100.0)	246 (99.2)	201 (99.5)	196 (99.0)	211 (99.1)	951 (99.3)	740 (99.3)
	Yes	2 (1.4)	-	2 (0.8)	1 (0.5)	2 (1.0)	2 (0.9)	7 (0.7)	5 (0.7)
	Unknown	-	-	-	28	33	21	82	61
Hypothyroidism, n (missing) n(%)	n (missing)	146 (0)	97 (0)	248 (0)	202 (0)	198 (0)	212 (0)	957 (0)	745 (0)
	No	128 (87.7)	88 (90.7)	228 (91.9)	181 (89.6)	173 (87.4)	187 (88.2)	857 (89.6)	670 (89.9)
	Yes	18 (12.3)	9 (9.3)	20 (8.1)	21 (10.4)	25 (12.6)	25 (11.8)	100 (10.4)	75 (10.1)
	Unknown	-	-	-	28	33	22	83	61
Vascular Disease, n(%)	n (missing)	146 (0)	97 (0)	248 (0)	229 (1)	229 (2)	232 (2)	1035 (5)	803 (3)
	No	128 (87.7)	75 (77.3)	218 (87.9)	192 (83.8)	186 (81.2)	186 (80.2)	857 (82.8)	671 (83.6)
	Yes	18 (12.3)	22 (22.7)	30 (12.1)	37 (16.2)	43 (18.8)	46 (19.8)	178 (17.2)	132 (16.4)
Moderate to Severe CKD, n(%)	n (missing)	146 (0)	97 (0)	248 (0)	230 (0)	231 (0)	234 (0)	1040 (0)	806 (0)
	No	131 (89.7)	82 (84.5)	224 (90.3)	206 (89.6)	220 (95.2)	216 (92.3)	948 (91.2)	732 (90.8)
	Yes	15 (10.3)	15 (15.5)	24 (9.7)	24 (10.4)	11 (4.8)	18 (7.7)	92 (8.8)	74 (9.2)

Study ID: TRI08888

GARFIELD: International Registry of Patients Newly Diagnosed with AF

**Table 06 : Clinical History**  
**Full Analysis Dataset : BRAZIL**



**Table 07 : Treatment for stroke prophylaxis  
Full Analysis Dataset : BRAZIL**

Variable	Statistics	Cohort 1 Retrospective patients (N=146) (n %)	Cohort 1 Prospective patients (N=97) (n %)	Cohort 2 (N=248) (n %)	Cohort 3 (N=230) (n %)	Cohort 4 (N=231) (n %)	Cohort 5 (N=234) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1040)	Total Prospective patients Cohorts 1 to 4 (N=806)
Baseline Treatment, n(%)	n (missing)	144 (0)	89 (0)	237 (0)	225 (0)	227 (0)	234 (0)	1012 (0)	778 (0)
	VKA	68 (47.2)	26 (29.2)	55 (23.2)	41 (18.2)	40 (17.6)	41 (17.5)	203 (20.1)	162 (20.8)
	VKA+AP	16 (11.1)	19 (21.3)	11 (4.6)	25 (11.1)	15 (6.6)	19 (8.1)	89 (8.8)	70 (9.0)
	FXA	1 (0.7)	1 (1.1)	33 (13.9)	39 (17.3)	44 (19.4)	45 (19.2)	162 (16.0)	117 (15.0)
	FXA+AP	1 (0.7)	5 (5.6)	9 (3.8)	6 (2.7)	8 (3.5)	19 (8.1)	47 (4.6)	28 (3.6)
	DTI	3 (2.1)	-	12 (5.1)	9 (4.0)	8 (3.5)	3 (1.3)	32 (3.2)	29 (3.7)
	DTI+AP	-	-	8 (3.4)	1 (0.4)	3 (1.3)	2 (0.9)	14 (1.4)	12 (1.5)
	AP	43 (29.9)	25 (28.1)	67 (28.3)	60 (26.7)	62 (27.3)	55 (23.5)	269 (26.6)	214 (27.5)
	NONE	12 (8.3)	13 (14.6)	42 (17.7)	44 (19.6)	47 (20.7)	50 (21.4)	196 (19.4)	146 (18.8)
	Unknown	2	8	11	5	4	-	28	28
	VKA±AP	84 (58.3)	45 (50.6)	66 (27.8)	66 (29.3)	55 (24.2)	60 (25.6)	292 (28.9)	232 (29.8)
	FXA±AP	2 (1.4)	6 (6.7)	42 (17.7)	45 (20.0)	52 (22.9)	64 (27.4)	209 (20.7)	145 (18.6)
	DTI±AP	3 (2.1)	-	20 (8.4)	10 (4.4)	11 (4.8)	5 (2.1)	46 (4.5)	41 (5.3)
	FXA/DTI	4 (2.8)	1 (1.1)	45 (19.0)	48 (21.3)	52 (22.9)	48 (20.5)	194 (19.2)	146 (18.8)
	FXA/DTI+AP	1 (0.7)	5 (5.6)	17 (7.2)	7 (3.1)	11 (4.8)	21 (9.0)	61 (6.0)	40 (5.1)
	FXA/DTI±AP	5 (3.5)	6 (6.7)	62 (26.2)	55 (24.4)	63 (27.8)	69 (29.5)	255 (25.2)	186 (23.9)
	AC	72 (50.0)	27 (30.3)	100 (42.2)	89 (39.6)	92 (40.5)	89 (38.0)	397 (39.2)	308 (39.6)
	AC+AP	17 (11.8)	24 (27.0)	28 (11.8)	32 (14.2)	26 (11.5)	40 (17.1)	150 (14.8)	110 (14.1)
	AC±AP	89 (61.8)	51 (57.3)	128 (54.0)	121 (53.8)	118 (52.0)	129 (55.1)	547 (54.1)	418 (53.7)

**Table 08: Treatment**  
**Full Analysis Dataset : BRAZIL**

	<b>Cohort 1 Retrospective (N=146) (n %)</b>	<b>Cohort 1 Prospective (N=97) (n %)</b>	<b>Cohort 2 (N=248) (n %)</b>	<b>Cohort 3 (N=230) (n %)</b>	<b>Cohort 4 (N=231) (n %)</b>	<b>Cohort 5 (N=234) (n %)</b>	<b>Total Prospective patients Cohorts 1 to 5 (N=1040)</b>	<b>Total Prospective patients Cohorts 1 to 4 (N=806)</b>
<b>Anti-platelet (non mutually exclusive groups)</b>								
ADP receptor/P2Y12 inhibitors	6 (4.1)	13 (13.4)	9 (3.6)	15 (6.5)	16 (6.9)	22 (9.4)	75 (7.2)	53 (6.6)
Prostaglandin Cox inhibitors	-	3 (3.1)	-	-	-	-	3 (0.3)	3 (0.4)
ASA	2 (1.4)	1 (1.0)	-	15 (6.5)	3 (1.3)	6 (2.6)	25 (2.4)	19 (2.4)
	54 (37.0)	42 (43.3)	88 (35.5)	80 (34.8)	87 (37.7)	80 (34.2)	377 (36.3)	297 (36.8)
<b>Anticoagulant drugs (non mutually exclusive groups)</b>								
VKA	85 (58.2)	52 (53.6)	75 (30.2)	70 (30.4)	56 (24.2)	60 (25.6)	313 (30.1)	253 (31.4)
FXa	3 (2.1)	13 (13.4)	51 (20.6)	49 (21.3)	55 (23.8)	64 (27.4)	232 (22.3)	168 (20.8)
DTI	3 (2.1)	-	22 (8.9)	12 (5.2)	14 (6.1)	5 (2.1)	53 (5.1)	48 (6.0)
Heparinoid	-	-	-	-	-	1 (0.4)	1 (0.1)	
Heparins	5 (3.4)	10 (10.3)	32 (12.9)	30 (13.0)	29 (12.6)	19 (8.1)	120 (11.5)	101 (12.5)
Other	1 (0.7)	2 (2.1)	3 (1.2)	1 (0.4)	2 (0.9)	3 (1.3)	11 (1.1)	8 (1.0)

**Table 09 : Risk scores**  
**Full Analysis Dataset : BRAZIL**

Variable	Statistics	Cohort 1 Retrospective patients (N=146) (n %)	Cohort 1 Prospective patients (N=97) (n %)	Cohort 2 (N=248) (n %)	Cohort 3 (N=230) (n %)	Cohort 4 (N=231) (n %)	Cohort 5 (N=234) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1040)	Total Prospective patients Cohorts 1 to 4 (N=806)
CHADS2 Score	n (missing)	142 (4)	93 (4)	239 (9)	224 (6)	229 (2)	227 (7)	1012 (28)	785 (21)
	Mean (SD)	2.0 (1.1)	2.1 (1.1)	1.9 (1.1)	1.9 (1.3)	2.0 (1.2)	1.9 (1.2)	1.9 (1.2)	1.9 (1.2)
	Median (IQR)	2.0 (1.0 to 3.0)	2.0 (1.0 to 3.0)	2.0 (1.0 to 3.0)	2.0 (1.0 to 2.0)	2.0 (1.0 to 3.0)	2.0 (1.0 to 3.0)	2.0 (1.0 to 3.0)	2.0 (1.0 to 3.0)
	Min to Max	0 to 5	0 to 5	0 to 5	0 to 5	0 to 5	0 to 6	0 to 6	0 to 5
CHADS2 score categories, n(%)	n (missing)	142 (4)	93 (4)	239 (9)	224 (6)	229 (2)	227 (7)	1012 (28)	785 (21)
	0	7 (4.9)	1 (1.1)	18 (7.5)	20 (8.9)	14 (6.1)	25 (11.0)	78 (7.7)	53 (6.8)
	1	44 (31.0)	29 (31.2)	79 (33.1)	75 (33.5)	70 (30.6)	67 (29.5)	320 (31.6)	253 (32.2)
	2	49 (34.5)	35 (37.6)	82 (34.3)	75 (33.5)	86 (37.6)	74 (32.6)	352 (34.8)	278 (35.4)
	3	27 (19.0)	14 (15.1)	42 (17.6)	25 (11.2)	26 (11.4)	40 (17.6)	147 (14.5)	107 (13.6)
	4	10 (7.0)	12 (12.9)	14 (5.9)	16 (7.1)	28 (12.2)	17 (7.5)	87 (8.6)	70 (8.9)
	5	5 (3.5)	2 (2.2)	4 (1.7)	13 (5.8)	5 (2.2)	2 (0.9)	26 (2.6)	24 (3.1)
6	-	-	-	-	-	2 (0.9)	2 (0.2)	-	
CHA2DS2- VASc Score	n (missing)	142 (4)	93 (4)	239 (9)	219 (11)	221 (10)	225 (9)	997 (43)	772 (34)
	Mean (SD)	3.3 (1.5)	3.6 (1.6)	3.1 (1.5)	3.2 (1.7)	3.4 (1.7)	3.2 (1.7)	3.2 (1.7)	3.2 (1.6)
	Median (IQR)	3.0 (2.0 to 4.0)	3.0 (3.0 to 4.0)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)
	Min to Max	0 to 7	1 to 7	0 to 7	0 to 8	0 to 8	0 to 9	0 to 9	0 to 8
CHA2DS2- VASc score categories, n(%)	n (missing)	142 (4)	93 (4)	239 (9)	219 (11)	221 (10)	225 (9)	997 (43)	772 (34)
	0	3 (2.1)	-	10 (4.2)	10 (4.6)	7 (3.2)	9 (4.0)	36 (3.6)	27 (3.5)
	1	13 (9.2)	6 (6.5)	28 (11.7)	32 (14.6)	25 (11.3)	35 (15.6)	126 (12.6)	91 (11.8)
	2	24 (16.9)	17 (18.3)	50 (20.9)	34 (15.5)	35 (15.8)	35 (15.6)	171 (17.2)	136 (17.6)
	3	46 (32.4)	27 (29.0)	53 (22.2)	54 (24.7)	55 (24.9)	48 (21.3)	237 (23.8)	189 (24.5)
	4	29 (20.4)	23 (24.7)	59 (24.7)	47 (21.5)	50 (22.6)	42 (18.7)	221 (22.2)	179 (23.2)

**Table 09 : Risk scores**  
**Full Analysis Dataset : BRAZIL**

Variable	Statistics	Cohort 1 Retrospective patients (N=146) (n %)	Cohort 1 Prospective patients (N=97) (n %)	Cohort 2 (N=248) (n %)	Cohort 3 (N=230) (n %)	Cohort 4 (N=231) (n %)	Cohort 5 (N=234) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1040)	Total Prospective patients Cohorts 1 to 4 (N=806)
	5	15 (10.6)	5 (5.4)	25 (10.5)	18 (8.2)	22 (10.0)	38 (16.9)	108 (10.8)	70 (9.1)
	6-9	12 (8.5)	15 (16.1)	14 (5.9)	24 (11.0)	27 (12.2)	18 (8.0)	98 (9.8)	80 (10.4)
HAS-BLED score	n (missing)	108 (38)	64 (33)	174 (74)	170 (60)	166 (65)	172 (62)	746 (294)	574 (232)
	Mean (SD)	1.6 (1.1)	1.8 (1.0)	1.4 (1.0)	1.5 (1.0)	1.2 (0.9)	1.4 (0.9)	1.4 (1.0)	1.4 (1.0)
	Median (IQR)	1.0 (1.0 to 2.0)	2.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)
	Min to Max	0 to 4	0 to 5	0 to 5	0 to 5	0 to 4	0 to 4	0 to 5	0 to 5
HAS-BLED score categories, n(%)	n (missing)	108 (38)	64 (33)	174 (74)	170 (60)	166 (65)	172 (62)	746 (294)	574 (232)
	0	15 (13.9)	5 (7.8)	35 (20.1)	30 (17.6)	38 (22.9)	23 (13.4)	131 (17.6)	108 (18.8)
	1	43 (39.8)	16 (25.0)	63 (36.2)	61 (35.9)	68 (41.0)	80 (46.5)	288 (38.6)	208 (36.2)
	2	31 (28.7)	31 (48.4)	59 (33.9)	56 (32.9)	46 (27.7)	50 (29.1)	242 (32.4)	192 (33.4)
	3	13 (12.0)	9 (14.1)	14 (8.0)	17 (10.0)	11 (6.6)	15 (8.7)	66 (8.8)	51 (8.9)
	4	6 (5.6)	2 (3.1)	2 (1.1)	5 (2.9)	3 (1.8)	4 (2.3)	16 (2.1)	12 (2.1)
	5	-	1 (1.6)	1 (0.6)	1 (0.6)	-	-	3 (0.4)	3 (0.5)

**Table 10: Treatment at baseline by CHA2DS2-VASc score  
Full Analysis Dataset : BRAZIL**

Cohort	CHA2DS2-VASc	VKA		VKA+AP		FXA		FXA+AP		DTI		DTI+AP		AP		NONE		UNKNOWN
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n
Cohort 1 retrospective	0	-	-	1	33.3	-	-	-	-	-	-	-	-	-	-	2	66.7	-
	1	7	53.8	-	-	-	-	-	-	-	-	-	-	4	30.8	2	15.4	-
	2	10	41.7	1	4.2	1	4.2	1	4.2	-	-	-	-	11	45.8	-	-	-
	3	23	51.1	6	13.3	-	-	-	-	2	4.4	-	-	10	22.2	4	8.9	1
	4	15	53.6	3	10.7	-	-	-	-	-	-	-	-	8	28.6	2	7.1	1
	5	7	46.7	2	13.3	-	-	-	-	1	6.7	-	-	4	26.7	1	6.7	-
	6-9	5	41.7	3	25	-	-	-	-	-	-	-	4	33.3	-	-	-	
Cohort 1 prospective	1	1	16.7	-	-	-	-	-	-	-	-	-	-	4	66.7	1	16.7	-
	2	7	46.7	2	13.3	-	-	1	6.7	-	-	-	-	3	20	2	13.3	2
	3	8	32	4	16	1	4	-	-	-	-	-	-	7	28	5	20	2
	4	6	30	7	35	-	-	2	10	-	-	-	-	4	20	1	5	3
	5	2	40	-	-	-	-	-	-	-	-	-	-	1	20	2	40	-
		6-9	2	14.3	6	42.9	-	-	2	14.3	-	-	-	-	3	21.4	1	7.1
Cohort 2	0	4	40	-	-	-	-	-	-	-	-	-	-	-	-	6	60	-
	1	7	25.9	-	-	5	18.5	-	-	-	-	-	-	8	29.6	7	25.9	1
	2	15	31.3	1	2.1	9	18.8	1	2.1	2	4.2	2	4.2	12	25	6	12.5	2
	3	13	26.5	5	10.2	3	6.1	1	2	3	6.1	3	6.1	16	32.7	5	10.2	4
	4	9	15.8	1	1.8	9	15.8	5	8.8	2	3.5	1	1.8	19	33.3	11	19.3	2
	5	4	16	3	12	6	24	-	-	4	16	-	-	7	28	1	4	-
		6-9	2	16.7	1	8.3	-	-	2	16.7	1	8.3	2	16.7	3	25	1	8.3
Cohort 3	0	1	10	-	-	3	30	-	-	-	-	-	-	2	20	4	40	-
	1	4	12.5	2	6.3	7	21.9	1	3.1	1	3.1	-	-	8	25	9	28.1	-
	2	7	20.6	2	5.9	5	14.7	-	-	3	8.8	-	-	10	29.4	7	20.6	-
	3	12	23.1	4	7.7	3	5.8	3	5.8	4	7.7	1	1.9	17	32.7	8	15.4	2
	4	7	14.9	7	14.9	12	25.5	-	-	-	-	-	-	12	25.5	9	19.1	-
	5	1	6.3	3	18.8	3	18.8	1	6.3	1	6.3	-	-	5	31.3	2	12.5	2

**Table 10: Treatment at baseline by CHA2DS2-VASc score**  
**Full Analysis Dataset : BRAZIL**

Cohort	CHA2DS2-VASc	VKA		VKA+AP		FXA		FXA+AP		DTI		DTI+AP		AP		NONE		UNKNOWN
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n
	6-9	7	30.4	5	21.7	4	17.4	1	4.3	-	-	-	-	4	17.4	2	8.7	1
Cohort 4	0	3	42.9	-	-	-	-	-	-	-	-	-	-	-	-	4	57.1	-
	1	1	4	2	8	9	36	-	-	2	8	-	-	2	8	9	36	-
	2	7	20	2	5.7	5	14.3	1	2.9	2	5.7	-	-	7	20	11	31.4	-
	3	7	13.2	2	3.8	12	22.6	2	3.8	2	3.8	2	3.8	20	37.7	6	11.3	2
	4	14	28.6	3	6.1	10	20.4	1	2	2	4.1	-	-	13	26.5	6	12.2	1
	5	5	22.7	2	9.1	4	18.2	-	-	-	-	1	4.5	9	40.9	1	4.5	-
	6-9	3	11.5	4	15.4	4	15.4	4	15.4	-	-	-	-	6	23.1	5	19.2	1
Cohort 5	0	-	-	-	-	3	33.3	-	-	1	11.1	-	-	1	11.1	4	44.4	-
	1	6	17.1	1	2.9	5	14.3	1	2.9	-	-	-	-	12	34.3	10	28.6	-
	2	5	14.3	5	14.3	3	8.6	6	17.1	1	2.9	2	5.7	7	20	6	17.1	-
	3	13	27.1	5	10.4	13	27.1	4	8.3	1	2.1	-	-	5	10.4	7	14.6	-
	4	4	9.5	5	11.9	7	16.7	5	11.9	-	-	-	-	10	23.8	11	26.2	-
	5	8	21.1	1	2.6	10	26.3	1	2.6	-	-	-	-	11	28.9	7	18.4	-
	6-9	2	11.1	2	11.1	2	11.1	2	11.1	-	-	-	-	8	44.4	2	11.1	-
Total Prospective patients Cohorts 1 to 5	0	8	22.2	-	-	6	16.7	-	-	1	2.8	-	-	3	8.3	18	50	-
	1	19	15.2	5	4	26	20.8	2	1.6	3	2.4	-	-	34	27.2	36	28.8	1
	2	41	24.6	12	7.2	22	13.2	9	5.4	8	4.8	4	2.4	39	23.4	32	19.2	4
	3	53	23.3	20	8.8	32	14.1	10	4.4	10	4.4	6	2.6	65	28.6	31	13.7	10
	4	40	18.6	23	10.7	38	17.7	13	6	4	1.9	1	0.5	58	27	38	17.7	6
	5	20	18.9	9	8.5	23	21.7	2	1.9	5	4.7	1	0.9	33	31.1	13	12.3	2
	6-9	16	17.2	18	19.4	10	10.8	11	11.8	1	1.1	2	2.2	24	25.8	11	11.8	5

**Table 10: Treatment at baseline by CHA2DS2-VASc score  
Full Analysis Dataset : BRAZIL**

Cohort	CHA2DS2-VASc	VKA		VKA+AP		FXA		FXA+AP		DTI		DTI+AP		AP		NONE		UNKNOWN	
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	
Total	0	8	29.6	-	-	3	11.1	-	-	-	-	-	-	2	7.4	14	51.9	-	
Prospective patients																			
Cohorts 1 to 4																			
	1	13	14.4	4	4.4	21	23.3	1	1.1	3	3.3	-	-	22	24.4	26	28.9	1	
	2	36	27.3	7	5.3	19	14.4	3	2.3	7	5.3	2	1.5	32	24.2	26	19.7	4	
	3	40	22.3	15	8.4	19	10.6	6	3.4	9	5	6	3.4	60	33.5	24	13.4	10	
	4	36	20.8	18	10.4	31	17.9	8	4.6	4	2.3	1	0.6	48	27.7	27	15.6	6	
	5	12	17.6	8	11.8	13	19.1	1	1.5	5	7.4	1	1.5	22	32.4	6	8.8	2	
	6-9	14	18.7	16	21.3	8	10.7	9	12	1	1.3	2	2.7	16	21.3	9	12	5	

**Table 11: Treatment at baseline by HAS-BLED score  
Full Analysis Dataset : BRAZIL**

Cohort	HAS-BLED	VKA		VKA+AP		FXA		FXA+AP		DTI		DTI+AP		AP		NONE		UNKNOWN	
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	
Cohort 1 retrospective	0	10	66.7	-	-	-	-	-	-	-	-	-	-	-	-	-	5	33.3	-
	1	27	62.8	-	-	1	2.3	-	-	3	7	-	-	10	23.3	2	4.7	-	
	2	13	41.9	4	12.9	-	-	-	-	-	-	-	-	13	41.9	1	3.2	-	
	3	1	8.3	5	41.7	-	-	-	-	-	-	-	-	5	41.7	1	8.3	1	
	4-9	2	33.3	3	50	-	-	-	-	-	-	-	-	1	16.7	-	-	-	
Cohort 1 prospective	0	4	80	-	-	-	-	-	-	-	-	-	-	-	-	1	20	-	
	1	8	50	1	6.3	1	6.3	1	6.3	-	-	-	-	3	18.8	2	12.5	-	
	2	6	23.1	11	42.3	-	-	1	3.8	-	-	-	-	4	15.4	4	15.4	5	
	3	1	12.5	2	25	-	-	2	25	-	-	-	-	3	37.5	-	-	1	
	4-9	-	-	1	50	-	-	1	50	-	-	-	-	-	-	-	-	-	1
Cohort 2	0	15	44.1	-	-	10	29.4	-	-	-	-	-	-	-	-	9	26.5	1	
	1	20	34.5	1	1.7	9	15.5	-	-	10	17.2	1	1.7	10	17.2	7	12.1	5	
	2	4	7.1	1	1.8	8	14.3	7	12.5	1	1.8	5	8.9	24	42.9	6	10.7	3	
	3	2	14.3	4	28.6	1	7.1	2	14.3	-	-	-	-	3	21.4	2	14.3	-	
	4-9	-	-	1	33.3	1	33.3	-	-	-	-	1	33.3	-	-	-	-	-	
Cohort 3	0	9	30	-	-	8	26.7	-	-	1	3.3	-	-	-	-	12	40	-	
	1	8	13.3	8	13.3	16	26.7	1	1.7	3	5	-	-	10	16.7	14	23.3	1	
	2	6	11.1	10	18.5	7	13	4	7.4	-	-	-	-	20	37	7	13	2	
	3	2	13.3	1	6.7	-	-	-	-	-	-	1	6.7	9	60	2	13.3	2	
	4-9	-	-	5	83.3	-	-	-	-	-	-	-	-	1	16.7	-	-	-	
Cohort 4	0	8	21.1	-	-	14	36.8	-	-	4	10.5	-	-	-	-	12	31.6	-	
	1	16	24.6	3	4.6	21	32.3	2	3.1	1	1.5	-	-	9	13.8	13	20	3	
	2	4	8.7	5	10.9	1	2.2	6	13	-	-	1	2.2	23	50	6	13	-	
	3	1	9.1	3	27.3	1	9.1	-	-	-	-	1	9.1	4	36.4	1	9.1	-	
	4-9	1	33.3	-	-	-	-	-	-	-	-	1	33.3	1	33.3	-	-	-	



**Table 11: Treatment at baseline by HAS-BLED score**  
**Full Analysis Dataset : BRAZIL**

Cohort	HAS-BLED	VKA		VKA+AP		FXA		FXA+AP		DTI		DTI+AP		AP		NONE		UNKNOWN	
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	
Cohort 5	0	7	30.4	-	-	4	17.4	-	-	-	-	-	-	-	-	-	12	52.2	-
	1	19	23.8	6	7.5	21	26.3	4	5	1	1.3	-	-	12	15	17	21.3	-	
	2	1	2	5	10	7	14	7	14	2	4	-	-	24	48	4	8	-	
	3	-	-	1	6.7	-	-	5	33.3	-	-	1	6.7	6	40	2	13.3	-	
	4-9	-	-	2	50	-	-	-	-	-	-	-	-	2	50	-	-	-	
Total Prospective patients Cohorts 1 to 5	0	43	33.1	-	-	36	27.7	-	-	5	3.8	-	-	-	-	46	35.4	1	
Total Prospective patients Cohorts 1 to 4	1	71	25.4	19	6.8	68	24.4	8	2.9	15	5.4	1	0.4	44	15.8	53	19	9	
	2	21	9.1	32	13.8	23	9.9	25	10.8	3	1.3	6	2.6	95	40.9	27	11.6	10	
	3	6	9.5	11	17.5	2	3.2	9	14.3	-	-	3	4.8	25	39.7	7	11.1	3	
	4-9	1	5.6	9	50	1	5.6	1	5.6	-	-	2	11.1	4	22.2	-	-	1	
	0	36	33.6	-	-	32	29.9	-	-	5	4.7	-	-	-	-	34	31.8	1	
Total Prospective patients Cohorts 1 to 4	1	52	26.1	13	6.5	47	23.6	4	2	14	7	1	0.5	32	16.1	36	18.1	9	
	2	20	11	27	14.8	16	8.8	18	9.9	1	0.5	6	3.3	71	39	23	12.6	10	
	3	6	12.5	10	20.8	2	4.2	4	8.3	-	-	2	4.2	19	39.6	5	10.4	3	
	4-9	1	7.1	7	50	1	7.1	1	7.1	-	-	2	14.3	2	14.3	-	-	1	
	0	36	33.6	-	-	32	29.9	-	-	5	4.7	-	-	-	-	34	31.8	1	

**Table 12: INR values and time in therapeutic range (TTR) during the first year of follow-up Cohorts 1 to 4  
Full Analysis Dataset : BRAZIL**

Variable	Statistics	Cohort 1 Prospective patients (N=45) (n %)	Cohort 2 (N=66) (n %)	Cohort 3 (N=66) (n %)	Cohort 4 (N=55) (n %)	Total Prospective patients Cohorts 1 to 4 (N=232)
TTR value, n(%)	n (missing)	28 (17)	23 (43)	18 (48)	17 (38)	86 (146)
	<65	22 (78.6)	21 (91.3)	13 (72.2)	14 (82.4)	70 (81.4)
	>=65	6 (21.4)	2 (8.7)	5 (27.8)	3 (17.6)	16 (18.6)
TTR	n (missing)	28 (17)	23 (43)	18 (48)	17 (38)	86 (146)
	Mean (SD)	40.0 (27.5)	31.5 (24.0)	44.6 (32.1)	45.5 (24.6)	39.8 (27.2)
	Median (IQR)	37.7 (20.3 to 62.8)	28.6 (8.9 to 45.2)	50.2 (9.5 to 71.9)	43.6 (31.6 to 55.9)	40.9 (17.5 to 60.0)
	Min to Max	0.0 to 90.7	0.0 to 83.6	0.0 to 100.0	0.0 to 92.3	0.0 to 100.0
INR value, n(%)	n	270	276	124	138	808
	2-3	85 (31.5)	83 (30.1)	53 (42.7)	55 (39.9)	276 (34.2)
	<2	114 (42.2)	137 (49.6)	61 (49.2)	55 (39.9)	367 (45.4)
	>3	71 (26.3)	56 (20.3)	10 (8.1)	28 (20.3)	165 (20.4)
INR	n	270	276	124	138	808
	Mean (SD)	2.5 (1.2)	2.3 (1.4)	2.1 (0.7)	2.5 (1.4)	2.4 (1.3)
	Median (IQR)	2.2 (1.5 to 3.1)	2.0 (1.4 to 2.7)	2.0 (1.5 to 2.5)	2.2 (1.7 to 2.8)	2.1 (1.5 to 2.8)
	Min to Max	1.0 to 9.0	1.0 to 8.9	1.0 to 5.3	0.9 to 10.0	0.9 to 10.0

**Table 13 :Event rates during the first year of follow-up Cohorts 1 to 4  
Full Analysis Dataset : BRAZIL**

Outcome	Cause	N	Events	Event rate /100 person-years	95% CI
All-cause death		806	40	5.27	(3.86 to 7.18)
	<b>Cardiovascular death</b>	806	15	1.98	(1.19 to 3.28)
	<b>Non-Cardiovascular death</b>	806	17	2.24	(1.39 to 3.60)
	<b>Undetermined cause</b>	806	8	1.05	(0.53 to 2.11)
Stroke/SE		806	11	1.46	(0.81 to 2.63)
Major bleed		806	8	1.06	(0.53 to 2.12)
Acute coronary syndrome		806	4	0.53	(0.20 to 1.40)
Congestive Heart Failure		806	30	4.04	(2.83 to 5.78)

**Table 14: Cause of death during the first year of follow-up Cohorts 1 to 4  
Full Analysis Dataset : BRAZIL**

		BRAZIL		
Outcome	Cause	N	Events	%
<b>Cardiovascular causes</b>	missing	15	1	6.67
	Myocardial infarction	15	1	6.67
	Ischaemic stroke	15	1	6.67
	Congestive heart failure	15	4	26.67
	Sudden or unwitnessed death	15	3	20.00
	Other	15	5	33.33
<b>Non-cardiovascular causes</b>	missing	17	2	11.77
	Respiratory failure	17	2	11.77
	Infection/sepsis	17	8	47.06
	Malignancy	17	1	5.88
	Other	17	4	23.53

**Table 15: Type of stroke during the first year of follow-up Cohorts 1 to 4  
Full Analysis Dataset :BRAZIL**

OUTCOME	BRAZIL		
	N	Events	%
Stroke(not including systemic embolism)	806	9	1.12
Primary Ischemic Stroke	806	4	0.50
<i>of which secondary hemorrhagic     ischemic</i>	806	1	0.12
Undetermined	806	5	0.62

**Table 16 : Mortality rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4  
Full Analysis Dataset : BRAZIL**

CHA2DS2-VASc	N	Person-Years	Events	Event rate /100 person-years	95% CI
0	27	26.85	0	-	-
1	91	87.70	2	2.28	(0.57 to 9.12)
2	136	129.27	6	4.64	(2.09 to 10.33)
3	189	175.78	9	5.12	(2.66 to 9.84)
4+	329	309.64	22	7.11	(4.68 to 10.79)
Unknown	34	30.08	1	3.33	(0.47 to 23.60)

**Table 17 : Stroke/SE rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4  
Full Analysis Dataset : BRAZIL**

CHA2DS2-VASc	N	Person-Years	Events	Event rate /100 person-years	95% CI
0	27	26.85	0	-	-
1	91	87.70	0	-	-
2	136	129.27	1	0.77	(0.11 to 5.49)
3	189	174.52	3	1.72	(0.55 to 5.33)
4+	329	306.31	7	2.29	(1.09 to 4.79)
Unknown	34	30.08	0	-	-

**Table 18 : Major bleeding rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4  
Full Analysis Dataset : BRAZIL**

CHA2DS2-VASc	N	Person-Years	Events	Event rate /100 person-years	95% CI
0	27	26.85	0	-	-
1	91	87.70	0	-	-
2	136	129.27	0	-	-
3	189	175.48	1	0.57	(0.08 to 4.05)
4+	329	306.71	7	2.28	(1.09 to 4.79)
Unknown	34	30.08	0	-	-